<DOC>
	<DOCNO>NCT02486016</DOCNO>
	<brief_summary>This Open-label , Non-Randomized , 3-way Crossover Bioequivalence Study compare fentanyl release heat brand name ( Duragesic ) generic ( Apotex Mylan ) fentanyl skin patch healthy adult .</brief_summary>
	<brief_title>Transdermal Patch CVD 2000 : The Effect Heat Fentanyl Release From Fentanyl Patches Healthy Adults</brief_title>
	<detailed_description>This research study intend determine effect heat FDA-approved fentanyl transdermal patch whether heat apply result fentanyl absorb skin without apply heat . This important give little known release fentanyl affect heat , particularly generic product also available counter . This study use fentanyl patch ( brand name generic patch ) approve Food Drug Administration ( FDA ) already sell counter customer United States , include placebo .</detailed_description>
	<mesh_term>Fentanyl</mesh_term>
	<criteria>1 . Men nonpregnant woman ethnic background age 18 45 year old . 2 . Subjects must nonsmoker ( must refrain use nicotinecontaining substance , include tobacco product ( e.g. , cigarette , cigar , chew tobacco , gum , patch electronic cigarette ) previous 2 month currently use tobacco product . 3 . Provide write informed consent initiation study procedure . 4 . Available followup plan duration study . 5 . Able communicate well investigator . 6 . Able adhere study protocol schedule . 7 . Subjects within ideal body weight ( BMI &gt; 17 ≤ 25 ) . 8 . Demonstrate comprehension protocol procedure knowledge study passing ( &gt; 70 % correct response ) write examination contain 20 multiple choice true false question cover aspect study include purpose , procedure , risk benefit . 9 . Subjects deem healthy judge Medically Accountable Investigator ( MAI ) determine medical history , physical examination , medication history . 10 . Negative urine drug screen test . 11 . Have normal blood pressure ( systolic : 90140 mmHg ; diastolic : 5090 mmHg ) heart rate ( 55100 bpm ) . 12 . Have normal screen laboratory WBC , Hgb , platelet , sodium , potassium , chloride , bicarbonate , BUN , creatinine , ALT , AST total bilirubin . 13 . Have normal screening laboratory urine protein urine glucose . 14 . Female subject must nonchildbearing potential ( define surgically sterile [ i.e . history hysterectomy tubal ligation ] postmenopausal 1 year ) , childbearing potential must nonpregnant time enrollment morning procedure , must agree use hormonal barrier birth control implant , injectables , combine oral contraceptive , intrauterine device ( IUDs ) , sexual abstinence , vasectomized partner . 15 . Agrees participate another clinical study study period . 16 . Agrees donate blood blood bank throughout participation study least 3 month last procedure day . 17 . Have normal ECG . 1 . Women pregnant , lactate breast feed positive serum pregnancy test enrollment morning procedure day . 2 . Smokers ( current use use previous 2 month nicotinecontaining substance , include tobacco product ( e.g. , cigarette , cigar , chew tobacco , gum , patch electronic cigarette ) . 3 . Participation ongoing investigational drug trial clinical drug trial . 4 . Abnormal Vital sign , define : Hypertension ( systolic blood pressure &gt; 140 mm Hg diastolic blood pressure &gt; 90 mm Hg ) rest 2 separate day ) Heart rate &lt; 55 rest 2 separate day Respiratory rate &gt; 20 5 . Temperature &gt; 38.0°C ( 100.4°F ) symptom acute selflimited illness upper respiratory infection gastroenteritis within 7 day application transdermal fentanyl patch . 6 . History chronic obstructive pulmonary disease . 7 . Active positive Hepatitis B , C , HIV serology . 8 . Positive urine drug screen test . 9 . Use prescription medication period 0 30 day overthe counter medication ( vitamin , herbal supplement birth control medication include ) period 0 3 day entry study . 10 . Donation loss great one pint blood within 60 day entry study . 11 . Any prior serious adverse reaction hypersensitivity fentanyl , naltrexone naloxone inactive ingredient patch ( alcohol , ethylene vinyl acetatecopolymer membrane hydroxyethyl cellulose , polyester , silicone adhesive , isopropyl myristate , octyldodecanol , polybutene , polyisobutene , dimethicone NF , polyolefin ) . 12 . Have diagnosis schizophrenia major psychiatric diagnosis mental illness ( e.g . major depression ) . 13 . Received experimental agent ( vaccine , drug , biologic , device , blood product medication ) within 1 month enrollment study expect receive experimental agent study . 14 . Any condition would , opinion Medically Accountable Investigator ( MAI ) , place subject unacceptable risk injury render subject unable meet requirement protocol . 15 . Inability communicate cooperate investigator . 16 . History consumption alcohol within 24 hour prior dose administration . 17 . Within 72 hour prior dose , use antihistamine use topical drug patch site . 18 . Subject obvious difference skin color arm presence skin condition , open sore , scar tissue , tattoo , coloration would interfere placement test article , skin assessment , reaction drug . 19 . Use monoamine oxidase inhibitor 21 day prior study . 20 . Failure pas opioid dependence challenge test procedure day application fentanyl patch . Each subject inject subcutaneously naloxone HCl ( 0.8 mg injection ) observe 45 minute sign symptom opioid withdrawal .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Bioequivalence</keyword>
	<keyword>Therapeutic Equivalency</keyword>
</DOC>